The Efficacy and Safety of an Immunosuppressive Regimen Including the Use of Mycophenolate Mofetil and an Interleukin-2 Monoclonal Antibody in Heart Transplant Patients

Background and Objectives:An immunosuppressive regimen including the use of mycophenolate mofetil (MMF) and an interleukin-2 monoclonal antibody (IL2mAb) has shown promise to prevent acute rejection after heart transplantation. There has been a lack of report on the evaluation of the efficacy and safety of this regimen in patients receiving heart transplants in Korea. Subjects and Methods:From November 1992 to December 2003, 111 consecutive patients who had received heart transplants in our institute were classified into two groups: patients who received the immunosuppressive regimen with MMF and an IL2mAb (group A, n=51) and patients who did not receive the regimen (group B, n=60). We compared the clinical outcomes of patients in each group including the survival rate and the occurrence of acute rejection and infection at 24 months post transplantation. Results:Both drugs were tolearated in all patients except in 5 patients who complained of gastrointestinal side effects due to MMF. Despite a longer ischemic time (137.4±54.6 vs. 92.3±25.8 hours, p<0.05) and a lower serum level of cyclosporine (212.3±66.8 vs. 259.1±62.1 ng/mL, p<0.05), the rate of treatment for acute rejection was lower in group A than in group B (16% vs. 53%, p<0.05). In addition, the median time to the first treatment for acute rejection was almost twice as long for group A as for group B (91 vs. 43 days, p<0.05). The 2-year survival rate and the incidence of major infection requiring hospitalization in both groups were 94% vs. 88% and 26% vs. 21%, respectively, which were not statistically different. Conclusion:An immunosuppressive regimen including the use of MMF and an IL2mAb is efficacious and safe as a prophylaxis against acute rejection without the increased risk of major infection in patients who have received heart transplants in Korea. (Korean Circulation J 2006;36:794-801)

[1]  J. Kovarik,et al.  A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  D. Renlund,et al.  Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  G. Tenderich,et al.  Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study. , 2005, European heart journal.

[4]  B. Meiser,et al.  Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure , 2004, Transplantation.

[5]  J. Tobis,et al.  Further analysis of the intravascular ultrasound data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients , 2004 .

[6]  D. Adu,et al.  Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials , 2003, BMJ : British Medical Journal.

[7]  L. Rostaing,et al.  Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. , 2003, Transplantation.

[8]  F. Vallés,et al.  Use of mycophenolate mofetil in patients with transplanted heart and renal insufficiency: the relevance of the pharmacokinetic study. , 2002, Transplantation proceedings.

[9]  J. Hosenpud,et al.  MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN PATIENTS SURVIVING THE INITIAL CARDIAC TRANSPLANT HOSPITALIZATION: AN ANALYSIS OF THE JOINT UNOS/ISHLT THORACIC REGISTRY , 2001, Transplantation.

[10]  M. Oz,et al.  Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy. , 2001, The Annals of thoracic surgery.

[11]  D. Mancini,et al.  Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. , 2000, The New England journal of medicine.

[12]  E. Shin,et al.  Meningitis due to Listeria Monocytogenes Following Orthotopic Heart Transplantation , 1998 .

[13]  D. Renlund,et al.  A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. , 1998, Transplantation.

[14]  D. Kabelitz.  Apoptosis, graft rejection, and transplantation tolerance. , 1998, Transplantation.

[15]  J. Lee,et al.  Heart Transplantaion : Early Results and 2-Year Survival , 1995 .

[16]  Y. Liao,et al.  Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. , 1993, Transplantation proceedings.

[17]  G. Berry,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[18]  A. Allison,et al.  Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. , 1990, Transplantation proceedings.

[19]  C. Barnard.  Human cardiac transplantation: An Evaluation of the first two operations performed at the Groote Schuur Hospital, Cape Town , 1968 .

[20]  J. Stockman.  Daclizumab to Prevent Rejection After Cardiac Transplantation , 2007 .

[21]  M. Gómez-Sánchez,et al.  Study of the safety and tolerability of Simulect® (basiliximab) versus OKT3 in heart transplantation , 2003 .

[22]  Seung‐Jung Park,et al.  Clinical Analysis of Infections Following Cardiac Transplantation , 2001 .

[23]  G. Schönrich,et al.  Multiple levels of peripheral tolerance. , 1993, Immunology today.